Show simple item record

dc.contributor.authorLew, TE
dc.contributor.authorAnderson, MA
dc.contributor.authorLin, VS
dc.contributor.authorHandunnetti, SM
dc.contributor.authorCame, NA
dc.contributor.authorBlombery, P
dc.contributor.authorWesterman, DA
dc.contributor.authorWall, M
dc.contributor.authorTam, CS
dc.contributor.authorRoberts, AW
dc.contributor.authorSeymour, JF
dc.identifierpii: 430089
dc.identifier.citationLew, T. E., Anderson, M. A., Lin, V. S., Handunnetti, S. M., Came, N. A., Blombery, P., Westerman, D. A., Wall, M., Tam, C. S., Roberts, A. W. & Seymour, J. F. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. BLOOD ADVANCES, 4 (1), pp.165-173.
dc.description.abstractThe highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the performance of peripheral blood (PB) compared with bone marrow (BM) assessment of MRD; the kinetics, clinicopathological associations, and longer-term outcomes of uMRD attainment and recrudescence; and the ability of venetoclax dose escalation to deepen responses. Among 16 patients who achieved PB uMRD and had contemporaneous BM assessments, 13 (81%) had confirmed BM uMRD, and patients with PB uMRD had outcomes at least as favorable as those with BM uMRD for time to progression, overall survival, and MRD recrudescence. Excluding 2 patients lacking earlier assessment, the median time to PB uMRD was 18 (range, 5-26) months, with 90% of instances achieved by 24 months. There was no new PB uMRD attainment after 24 months without treatment intensification. The dominant association with earlier attainment of uMRD was concurrent rituximab (P = .012). Complex karyotype was associated with inferior uMRD attainment after 12 months of therapy (P = .015), and patients attaining uMRD whose disease harbored TP53 abnormalities demonstrated a trend toward earlier recrudescence (P = .089). Of patients who received venetoclax dose escalations, 4 (27%) of 15 achieved improvements in response. For patients with R/R CLL receiving venetoclax, PB uMRD commonly correlates with BM uMRD and is associated with a comparable longer-term prognosis. Concurrent rituximab augments uMRD attainment, but dose escalation and further treatment beyond 24 months infrequently deepen responses.
dc.titleUndetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
dc.typeJournal Article
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.affiliation.departmentCentre for Cancer Research
melbourne.affiliation.departmentClinical Pathology
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBlood Advances
melbourne.openaccess.statusPublished version
melbourne.contributor.authorCame, Neil
melbourne.contributor.authorWesterman, David
melbourne.contributor.authorSeymour, John
melbourne.contributor.authorRoberts, Andrew
melbourne.contributor.authorTam, Constantine
melbourne.contributor.authorWall, Meaghan
melbourne.contributor.authorHandunnetti, Sasanka
melbourne.contributor.authorAnderson, Mary Ann
melbourne.contributor.authorBlombery, Piers
melbourne.accessrightsAccess this item via the Open Access location

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record